The AIM-HIGH trial found that adding high-dose extended-release niacin gave no further benefit to patients with atherosclerotic heart disease whose LDL was already well controlled on statins. Boden presented the results at the AHA meeting and in NEJM.
Section archive
Niacin
- All desks
- Abortion
- Accutane
- Acetaminophen
- Acid Reflux
- Acidic Foods
- Acne
- Acrylamide
- Acupuncture
- Additives
- ADHD
- Adiposity
- Advisories
- Aerobic Exercise
- Aflatoxin
- Agave
- Agent Orange
- Aging
- Agriculture
- AIDS
- Air Pollution
- Airline Passengers
- Airport
- ALA
- Alcohol
- Alcoholic Beverage
- Alerts
- Allergy
- Alli
- Aloe Vera
- ALS
- Alternative Medicine
- Aluminum
- Alzheimer's
- Amalgam
- AMD
- Ampyra
- Amygdala
- Anal Cancer
- And
- Anemia
- Angiogenesis
- Animal Protein
- Animals
- Anorexia
- Anthocyanins
- Anthrax
- Anti-Angiogenesis
- Anti-Obesity
- Antibacterial
- Antibiotic
Nutrition
You can lower cholesterol, but can't cut cardiovascular risk
A trial halted 18 months early found that adding niacin to statins in 3,412 high-risk patients raised HDL and lowered LDL but did not cut heart attacks, strokes or hospitalizations for acute coronary problems or revascularization.
Nutrition
Vitamin B niacin offers no extra benefits to statin therapy
In 145 Baltimore patients over 65 with existing atherosclerosis, adding 1,500 mg of extended-release niacin to statin therapy did not further reduce arterial wall thickness, though LDL fell 5 percent and HDL rose 14 percent. Lima says any niacin benefit lies elsewhere.
3 stories